1. The Tumour Suppressor CYLD Is Required for Clathrin-Mediated Endocytosis of EGFR and Cetuximab-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma
   Rin Liu et al, 2021, Cancers CrossRef
2. Molecular mechanisms of resistance to monoclonal antibodies therapy patients with squamous cell carcinoma of the tongue and mucosa of the oral cavity
   L. Yu. Vladimirova et al, 2019, Malignant tumours CrossRef
3. Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers
   Sandra Ortiz-Cuaran et al, 2021, Frontiers in Oncology CrossRef
4. Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through activation of the EGFR/AKT pathway
   Yuichi OHNISHI et al, 2016, Japanese Journal of Oral and Maxillofacial Surgery CrossRef
5. Anti-EGFR monoclonal antibody Cetuximab displays potential anti-cancer activities in feline oral squamous cell carcinoma cell lines
   Gennaro Altamura et al, 2022, Frontiers in Veterinary Science CrossRef
6. Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines
   Laura Lattanzio et al, 2015, Investigational New Drugs CrossRef
7. Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma
   Won Jong Jin et al, 2020, Frontiers in Immunology CrossRef
8. Mouse Models for Head and Neck Squamous Cell Carcinoma
   J. Zhou et al, 2024, Journal of Dental Research CrossRef